PriceTargets.com logo

Kintara Therapeutics - KTRA Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $0.00
  • Forecasted Upside: -100.00%
  • Number of Analysts: 2
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$7.05 As of 02/6/2023 01:00 AM ET
▲ +0.21 (3.07%)

This chart shows the closing price for KTRA by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Kintara Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KTRA and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KTRA

Analyst Price Target is $0.00
▼ -100.00% Downside Potential
This price target is based on 2 analysts offering 12 month price targets for Kintara Therapeutics in the last 3 months. The average price target is $0.00, with a high forecast of $0.00 and a low forecast of $10,000,000.00. The average price target represents a -100.00% upside from the last price of $7.05.

This chart shows the closing price for KTRA for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 2 contributing investment analysts is to hold stock in Kintara Therapeutics. This rating has held steady since September 2022, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 1 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
8/16/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/14/2021
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/12/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
5/13/2022
  • 0 strong buy ratings
  • 2 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
8/11/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/9/2022
  • 0 strong buy ratings
  • 1 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
1/8/2023
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
2/7/2023

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/29/2022Maxim GroupDowngradeBuy ➝ HoldLow
5/16/2022Dawson JamesDowngradeBuy ➝ NeutralLow
1/20/2022HC WainwrightLower TargetBuy$300.00 ➝ $150.00High
10/8/2021Maxim GroupInitiated CoverageBuy$150.00High
9/30/2021AegisLower TargetBuy$350.00 ➝ $250.00Low
9/28/2021HC WainwrightInitiated CoverageBuy$300.00High
7/2/2021Maxim GroupReiterated RatingBuy$300.00N/A
2/3/2021AegisBoost TargetBuy$300.00 ➝ $350.00High
11/20/2020Maxim GroupInitiated CoverageBuy$150.00High
10/1/2020AegisReiterated RatingBuy$300.00High
9/14/2020AegisInitiated CoverageBuy$300.00High
7/28/2020Maxim GroupReiterated RatingBuy$100.00Medium
6/23/2020Maxim GroupInitiated CoverageBuy$100.00Medium
6/6/2020Maxim GroupInitiated CoverageBuy$100.00High
5/14/2020Maxim GroupReiterated RatingBuy$100.00Low
11/15/2019Maxim GroupReiterated RatingBuyLow
9/6/2019Maxim GroupInitiated CoverageBuyHigh
7/11/2019Dawson JamesReiterated RatingBuyHigh
5/23/2018HC WainwrightSet TargetBuy$6,000.00Medium
(Data available from 2/7/2018 forward)

News Sentiment Rating

-1.22 (Sell)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 2 very negative mentions
Mentions as of
7/12/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
8/11/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
9/10/2022
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
10/10/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/9/2022
  • 2 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 7 very negative mentions
Mentions as of
12/9/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
Mentions as of
1/8/2023
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions
Mentions as of
2/7/2023

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 2 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

  • No negative mentions tracked during this time.

Positive

  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Kintara Therapeutics logo
Kintara Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of new cancer therapies. Its product pipeline includes VAL-083 and REM-001. The company was founded by Jeffrey A. Bacha, Dennis M. Brown, and William J. Garner on June 24, 2009 and is headquartered in San Diego, CA.
Read More

Today's Range

Now: $7.05
Low: $6.60
High: $7.10

50 Day Range

MA: $7.88
Low: $5.74
High: $14.80

52 Week Range

Now: $7.05
Low: $3.50
High: $42.00

Volume

29,474 shs

Average Volume

29,416 shs

Market Capitalization

$11.42 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.01

Frequently Asked Questions

What sell-side analysts currently cover shares of Kintara Therapeutics?

The following Wall Street sell-side analysts have issued reports on Kintara Therapeutics in the last twelve months: Dawson James, and Maxim Group.
View the latest analyst ratings for KTRA.

What is the current price target for Kintara Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Kintara Therapeutics in the last year. has the lowest price target set, forecasting a price of $10,000,000.00 for Kintara Therapeutics in the next year.
View the latest price targets for KTRA.

What is the current consensus analyst rating for Kintara Therapeutics?

Kintara Therapeutics currently has 2 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in KTRA, but not buy more shares or sell existing shares.
View the latest ratings for KTRA.

What other companies compete with Kintara Therapeutics?

Other companies that are similar to Kintara Therapeutics include Bellicum Pharmaceuticals, Xenetic Biosciences, Agile Therapeutics, Cingulate and NexImmune. Learn More about companies similar to Kintara Therapeutics.

How do I contact Kintara Therapeutics' investor relations team?

Kintara Therapeutics' physical mailing address is 12707 HIGH BLUFF DR. SUITE 200, SAN DIEGO CA, 92130. The company's listed phone number is (858) 350-4364 and its investor relations email address is [email protected] The official website for Kintara Therapeutics is www.kintara.com. Learn More about contacing Kintara Therapeutics investor relations.